Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as trastuzumab and bevacizumab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy
together with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: This clinical trial is studying how well giving docetaxel and carboplatin together
with trastuzumab and bevacizumab works in treating patients with stage I, stage II, or stage
III breast cancer and bone marrow micrometastases.